ArticlePediatric blood & cancer2017

Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program.

Raushan T Kurmasheva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.